Subscribe to RSS
DOI: 10.1055/s-2001-15886
Georg Thieme Verlag Stuttgart ·New York
Anti-inflammatoires non stéroïdiens (AINS) et inflammation oculaire
Nonsteroidal antiinflammatory drugs (NSAID) and ocular inflammation - a reviewPublication History
Publication Date:
31 December 2001 (online)
Nichtsteroidale Entzündungshemmer und Augenentzündungen - eine Übersicht
Hintergrund Die okuläre Entzündung wird von komplexen Vorgängen bestimmt, welche unter anderem für die Aufhebung der Blut-Augen-Schranke und die Chemotaxis von Entzündungszellen zum Auge verantwortlich sind.
Material und Methoden Zusammenfassung der Eigenschaften und Nebenwirkungen der NSAID gemäß Literatur.
Ergebnisse Entzündungsmediatoren, insbesondere Prostaglandine und Zytokine, sind die wesentlichen steuernden Faktoren. Obwohl die hemmende Wirkung des Aspirins und der nichtsteroidalen Entzündungshemmer (NSAID) seit 1971 bekannt ist, wurden doch die beiden Isoenzyme der Zyklooxygenase erst kürzlich beschrieben. Die konstitutive Form des Cox-1 ist für die Produktion des PGE2 verantwortlich, welches in der gastrointestinalen Zytoprotektion, der Plättchen-Aggregation und dem Erhalt der Nierenfunktion mitspielt. Die Produktion des Isoenzymes Cox-2 wird durch eine Entzündung ausgelöst. Die Anwesenheit von COX-2 konnte in gewissen Augengeweben nachgewiesen werden (Hornhautepithel und RP-Epithel usw. …). Klinisch werden NSAID erfolgreich eingesetzt, um Entzündungen und deren Schmerzen zu kontrollieren, perioperativ eine Mydriase zu unterhalten und postoperativ dem zystoiden Makulaödem vorzubeugen.
Schlussfolgerungen Die NSAID sind wirkungsvolle Entzündungshemmer. Vorsicht ist jedoch angebracht bei trockenen Augen oder bei Allergiebereitschaft.
Background Ocular inflammation is regulated by complicated mechanism that are responsible for the rupture of the blood-ocular barrier and the attraction of leukocytes towards the eye. This cellular trafficking is regulated by the liberation of inflammatory mediators and cytokines.
Materials and methods The main effects of prostaglandins that are described in the literature were rewied.
Results Despite the fact that the inhibitory action of aspirin and NSAIDs on prostaglandins secretion is known since 1971, it is quite recently that two isoenzymes of cyclooxygenase were discovered. The Cyclooxygenase-1 (COX-1) is constitutive and is responsible for the production of PGE2. This prostaglandin is related to the housekeeping functions such as gastric protection, platelet aggregation and maintenance of renal function. The expression of the cyclooxygenase 2 (COX-2) is induced by inflammation. The presence of COX-2 could be demonstrated in many ocular tissues (corneal epithelium and endothelium, pigmentary epithelium etc. …) The use of NSAIDs in clinical practice allows a good control of ocular inflammation, of pain, of the maintenance of a good mydriasis during surgery and are impending the onset of postoperative cystoid macular edema.
Conclusion Prostaglandins are potent anti-inflammatory agents but their use is limited in the presence of severe dry eye syndrome or allergy towards NSAIDs.
Schlüsselwörter
Nichtsteroidale Entzündungshemmer - Prostaglandine - Diclofenac Na - Flurbiprofen - Ketorolac
Key words
NSAIDs - prostaglandin - diclofenac Na - flurbiprofen - ketorolac
Références
- 01 Ayo C. A toxic ocular reaction. II. On the nature of the reaction. J Immunology. 1942; 46 127-132
- 02 Rietschel E T, Brade H. Bacterial endotoxins. Scientific American. 1992; 267 54-61
- 03 Masferrer J L, Kulkarni P S. Cyclooxygenase-2 inhibitors: a new approach to the therapy of ocular inflammation. Surv Ophthalmol. 1997; 41 S35-S40
- 04 Woodward D F, Regan J W, Lake S, et al. The molecular biology and ocular distribution of prostanoid receptors. Surv Ophthalmol. 1997; 41 S15-S21
- 05 Hawkey C J. Cox-2 inhibitors. Lancet. 1999; 353 307-314
- 06 Hayllar J, Bjarnason I. NSAIDs, Cox-2 inhibitors, and the gut. Lancet. 1995; 346 521-522
- 07 Othenin-Girard P, Tritten J-J, Pittet N, et al. Dexamethasone versus diclofenac sodium eyedrops to treat inflammation after cataract surgery. J Cataract Refract Surgery. 1994; 20 9-12
- 08 Diestelhorst M, Schmidl B, Konen W, et al. Efficacy and tolerance of diclofenac sodium 0.1 %, flurbiprofen 0.03 %, and indomethacin in controlling postoperative inflammation. J Cataract Refract Surg. 1996; 22 788-793
- 09 Ellis P P, Pfoff D S, Bloedow D C, et al. Intraocular diclofenac and furbiprofen concentrations in human aqueous humor following topical administration. J Ocular Pharmacol. 1994; 10 677-682
- 10 Gass J DM, Norton E WD. Cystoid macular edema and papilledema following cataract extraction. Arch Ophthalmol. 1966; 76 646-661
- 11 Quentin C-D, Behrens-Baumann W, Gaus W. Prophylaxe des zystoiden Makulaödems mit Diclofenac-Augentropfen bei i.c. Kataractextraction it Choyce-Mark-IX-Vorderkammerlinse. Fortschr Ophthalmol. 1989; 86 546-549
- 12 Flach A J, Dolan B J, Irvine A R. Effectiveness of ketorolac tromethamine 0.5 % ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol. 1987; 103 479-486
- 13 Miyake K. Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A Preliminary report. Graefes Arch Clin Exp Ophthalmol. 1977; 203 81-88
- 14 Nichols J, Snyder R W. Topical nonsteroidal anti-inflammatory agents in ophthalmology. Curr Opin Ophthalmol. 1998; 9 40-44
- 15 Koay P. The emerginf roles of topical non-steroidal anti-inflammatory agents in ophthalmology. Br J Ophthalmol. 1996; 80 480-485
- 16 Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long-term cystoid macular edema. J Cataract Refract Surg. 1997; 23 1183-1189
- 17 Guex-Crosier Y, Othenin-Girard P, Herbort C P. Differential treatment of postoperative and uveitis-induced inflammatory cystoid macular edema. Klin Monatsbl Augenheilkd. 1992; 200 367-373
- 18 Chen X, Gallar J, Belmonte C. Reduction by anti-inflammatory drugs of the response of corneal sensory nerve fibers to chemical irritation. Invest Ophthalmol Vis Sci. 1997; 38 1944-1953
- 19 Montard M, Chopin C, Delbosc G, et al. Tetracaïne versus diclofenac dans le traitement de la douleur après photokératectomie réfractive. J Fr Ophtalmol. 1999; 22 14-20
- 20 McDonald M. Comparison of the effectiveness of 4 anti-inflammatory drops in relieving photophobia after pupil dilation. J Cataract Refract Surg. 1999; 25 405-410
- 21 Sitenga G L, Ing E B, Vand Dellen R G, et al. Asthma caused by topical application of ketoralac. Ophthalmology. 1996; 103 890-892
- 22 Flaxel C J, Black R K. Aspirin is a hazard for vitreoretinal surgery. Br J Ophthalmol. 1996; 80 486
- 23 Ferrari M. Use of topical nonsteroidal anti-inflammatory drugs after photorefractive keratectomy. J Refract Corneal Surg. 1994; 10 287-289
- 24 Nassaralla B, Szerenyi K, Wang X W, et al. Effect of diclofenac on corneal haze after photorefractive keratectomy in rabbits. Ophthalmology. 1995; 102 469-474
- 25 Vane J R, Botting R M. New insights into the mode of action of anti-inflammatory drugs. Inflamma Res. 1995; 44 1-10
- 26 McCarey B, Napalkov J A, Pippen P A, et al. Corneal wound healing strength with topical anti-inflammatory drugs. Cornea. 1995; 14 290-294
- 27 Flach A. Topically applied nonsteroidal anti-inflammatory drugs and corneal problems: an interim review and comment. Ophthalmology. 2000; 107 1224-1226